Back to News & Events

Entrepreneurship Lab NYC (ELabNYC) – 2019 Program Application Open

LifeSci NYC has announced the launch of the seventh year of its life sciences entrepreneur training and networking program – Entrepreneurship Lab NYC (ELabNYC). Applications for the 2019 program are now being accepted.

ELabNYC is a six-month entrepreneurship training and networking program for scientists and engineers who are ready to launch their exciting ventures from New York City–based research institutions. Applications are due Monday, October 22, 2018.

Apply Here

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2043 [post_author] => 3 [post_date] => 2016-02-18 19:40:38 [post_date_gmt] => 2016-02-18 19:40:38 [post_content] => Piraye Yurttas Beim, co-founder and CEO of Celmatix was named to “The Fortune Entrepreneurs List”. Celmatix's technology enabled products analyze big data and genomics to optimize the treatment of infertility and allow for proactive fertility management. Read the feature on Dr. Beim on Fortune.com. [post_title] => Celmatix CEO Named to Fortune’s Entrepreneurs List [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => celmatix-ceo-named-to-fortunes-entrepreneurs-list [to_ping] => [pinged] => [post_modified] => 2016-03-29 19:42:38 [post_modified_gmt] => 2016-03-29 19:42:38 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2043 [menu_order] => 190 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 1001 [post_author] => 1 [post_date] => 2014-06-04 05:56:55 [post_date_gmt] => 2014-06-04 05:56:55 [post_content] => CFB Client Company, Intensity Therapeutics, Inc. established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity?s in situ chemovaccination products using in vivo models of cancer. Read the full press release here. [post_title] => Intensity Therapeutics Awarded CRADA from National Cancer Institute [post_excerpt] => A CFB Client Company established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => intensity-therapeutics-awarded-crada-from-national-cancer-institute [to_ping] => [pinged] => [post_modified] => 2015-01-28 17:06:52 [post_modified_gmt] => 2015-01-28 17:06:52 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1001 [menu_order] => 229 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3228 [post_author] => 3 [post_date] => 2019-04-08 14:42:13 [post_date_gmt] => 2019-04-08 14:42:13 [post_content] => Thinking of starting a life science company? The Center for Biotechnology can provide access to a compelling, pre-screened pipeline of academic technologies, milestone based incentives, access to early-stage funding opportunities, and staff support to serve as your virtual start-up team. The Long Island, NY region has a well demonstrated capacity for innovation, serving as home to Cold Spring Harbor Laboratory, Stony Brook University, the Feinstein Institute at Northwell Health, and Brookhaven National Laboratory, among others. Sample technologies that have emerged from the region include Magnetic Resonance Imaging (MRI), ReoPro®; Xiaflex®; Cavistat®; Oracea®, and 3D Virtual Colonoscopy. More details on the BioEntrepreneur-in-Residence initiative can be found here. Women and underrepresented minorities are encouraged to inquire. If you are interested in the initiative or would like to discuss further, please contact Diane Fabel at diane.fabel@stonybrook.edu or call 631.632.1582. [post_title] => Call for Entrepreneurs! [post_excerpt] => If you are taking the entrepreneurial leap for the first time, or are a seasoned entrepreneur looking for their next venture, the Center for Biotechnology would like to hear from you. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => call-for-entrepreneurs [to_ping] => [pinged] => https://centerforbiotechnology.org/what-we-do/business-development/ [post_modified] => 2019-05-03 16:38:03 [post_modified_gmt] => 2019-05-03 16:38:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3228 [menu_order] => 97 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Celmatix CEO Named to Fortune’s Entrepreneurs List

More Information

Intensity Therapeutics Awarded CRADA from National Cancer Institute

More Information

Call for Entrepreneurs!

More Information